Ryo Koyama

TL;DR: The RELAY trial as mentioned in this paper evaluated erlotinib, an EGFR tyrosine kinase inhibitor (TKI) standard of care, plus ramucirumab, a human IgG1 VEGFR2 antagonist, or placebo in patients with untreated EGFR-mutated metastatic NSCLC.

TL;DR: Alectinib continued to demonstrate superiority in IRF-assessed PFS versus crizotinib in AlK-inhibitor-naïve ALK-positive NSCLC, with a favorable safety profile, at the final PFS analysis.

TL;DR: It is demonstrated that the new hydration protocol comprising supplementation with magnesium without furosemide could prevent the nephrotoxicity induced by cisplatin and pemetrexed without affecting the treatment outcome.

TL;DR: Carboplatin plus weekly paclitaxel must be administered carefully to advanced NSCLC patients with ILD that is detected on chest X-rays after a sufficient evaluation of the risks and the benefits.

TL;DR: The incidence of PEM-related pulmonary toxicity was significantly higher amongst NSCLC patients with IIPs than among those without IIPs, and Multivariate analyses demonstrated that IIPs was the only significant independent risk factor for Pem- related pulmonary toxicity.